, /PRNewswire/ -- , (Nasdaq: ), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today announced that the Company will be participating in the next Emerging Growth Conference, a virtual forum for institutional and retail investment community engagement. Cadrenal's presentation will be on , at . A webcast link of the presentation can be found on the investor relations page of the Company's website or accessed .
If interested investors are not able to join the live event, an archived webcast will be available on and the Emerging Growth YouTube Channel, . Management will also host one-on-one investor meetings after the Conference. To request a virtual one-on-one meeting with the Company's management team, please contact your Emerging Growth Conference representative or email the Company's investor relations team at .
Cadrenal Therapeutics is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions who require lifelong anticoagulation. Tecarfarin has orphan drug designation from the FDA for the prevention of thrombosis and thro.
